Attendance, uptake and prescribing rates for NHS health checks are all lower than originally anticipated, according to a systematic review of data published in the British Journal of General Practice (BJGP).
Read More
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
Read More
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
Read More
